Timothy Eisen

6.2k citations

17 papers · 3.5k indexed · 3 hit papers · h-index 10

Impact in

Cancer Research top 2%
- Cancer Genomics and Diagnostics
Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Cancer Research 8
- Cancer Genomics and Diagnostics 7
- Cancer, Hypoxia, and Metabolism 2
Pulmonary and Respiratory Medicine 13
- Renal cell carcinoma treatment 11

Co-authors: Bernard Escudier Ferrán Algaba Alan Horwich Jean Jacques Patard Manuela Schmidinger Camillo Porta Vincent Khoo Athena Matakidou
Journals: Journal of Clinical Oncology (6 papers)Annals of Oncology (2 papers)Clinical Cancer Research (1 paper)Nature Genetics (1 paper)European Journal of Human Genetics (1 paper)
Partner nations: United Kingdom United States Spain

In The Last Decade

Timothy Eisen

17 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial 2015 · 688 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 The Lancet Oncology
2014 Annals of Oncology
2008 Nature Genetics

Peers

Countries citing papers authored by Timothy Eisen

Since Specialization

Citations

This map shows the geographic impact of Timothy Eisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Eisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Eisen more than expected).

Fields of papers citing papers by Timothy Eisen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Eisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Eisen. The network helps show where Timothy Eisen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Timothy Eisen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Timothy Eisen Line = papers co-authored together Timothy Eisen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	MA 11.02 Circulating Tumor DNA in Early Stage NSCLC: High Sensitivity Analysis in Low Burden Disease. LUCID Study Update Journal of Thoracic Oncology ·Andrea Ruiz-Valdepeñas, Katrin Heider, Maira Ana Kandler, Wendi Qian, Charles Massie, Dineika Chandrananda, Christopher G. Smith, Davina Gale, Laio Gastaldello Zambello, (unknown), A Stone, F. Limbourg, Timothy Eisen, Doris M. Rassl, Susan Harden, Robert C. Rintoul, Nitzan Rosenfeld	2017	2
2	A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis Clinical Cancer Research ·Robert E. Hawkins, Martin Gore, Yaroslav Shparyk, J. Giribon, Oleg Gladkov, Fekadu Dadi Abel, Mihai Hârza, Łukasz Sługocki, Igor Bondarenko, Petr Karlov, O. B. Kаryakin, Р. Ш. Хасанов, Gunnar Hedlund, G. Forsberg, Örjan Nordle, Timothy Eisen	2016	23
3	Cytochrome P450 AlleleCYP3A71CAssociates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer Cancer Research* ·Nichola Johnson, Juliana Sánchez González, Gabriele Migliorini, Nick Orr, Peter Broderick, Daniel Catovsky, Athena Matakidou, Timothy Eisen, Kiran Kamal Prasad, Frank Dudbridge, Julian Peto, Isabel dos‐Santos‐Silva, Alan Ashworth, Gillian Ross, Richard S. Houlston, Olivia Fletcher	2016	26
4	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial The Lancet Oncology ·Robert J. Motzer, Thomas E. Hutson, Hilary Glen, M. Dror Michaelson, Ana M. Molina, Timothy Eisen, Jacek Jassem, Jakub Żołnierek, Pablo Maroto, Begoña Mellado, Bohuslav Melichar, Jiří Tomášek, Alton B. Kremer, Hanjoo Kim, Karen Wood, Corina E. Dutcus, James Larkin Hit paper breakdown →	2015	688
5	Deciphering associations for lung cancer risk through imputation and analysis of 12 316 cases and 16 831 controls European Journal of Human Genetics ·Yufei Wang, Yongyue Wei, Valérie Gaborieau, Jianxin Shi, Younghun Han, Maria Timofeeva, Li Su, Yafang Li, Timothy Eisen, Christopher I. Amos, Maria Teresa Landi, David C. Christiani, James McKay, Richard S. Houlston	2015	9
6	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology ·Bernard Escudier, Camillo Porta, Manuela Schmidinger, Ferrán Algaba, Jean Jacques Patard, Vincent Khoo, Timothy Eisen, Alan Horwich Hit paper breakdown →	2014	1823
7	Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride. Journal of Clinical Oncology ·Murray O. Robinson, Bin Feng, Richard Nicoletti, Anna Berkenblit, Andrew Strahs, Brooke Esteves, Timothy Eisen, Robert J. Motzer	2013	1
8	Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. Journal of Clinical Oncology ·Robert J. Motzer, Timothy Eisen, Thomas E. Hutson, Cezary Szczylik, Mizue Krygowski, Andrew Strahs, Brooke Esteves, Andrew Krivoshik, Anna Berkenblit, Dmitry Nosov	2013	21
9	Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology ·Thomas E. Hutson, Dmitry Nosov, Timothy Eisen, Oleg Lipatov, Piotr Tomczak, Anna Alyasova, Mihai Hârza, М. И. Коган, Brenda Sylviasyah, Cezary Szczylik, Andrew Strahs, Brooke Esteves, Anna Berkenblit, Robert J. Motzer	2013	10
10	A Plasma Proteomic Signature Predicts Outcomes in a Phase 3 Study of Gemcitabine (G) + Cisplatin (C) ± Sorafenib in First Line Stage IIIB or IV NSCLC Annals of Oncology ·Johan Vansteenkiste, Luis Paz‐Ares, Timothy Eisen, David F. Heigener, Wilfried Eberhardt, Michael Thomas, Caicun Zhou, Armando Santoro, Chetan Lathia, Heinrich Röder	2012	2
11	A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology ·Robert J. Motzer, Pankaj Bhargava, Jessica Foss, Mohammed Al-Adhami, William J. Slichenmyer, Dmitry Nosov, Timothy Eisen, Cora N. Sternberg, Thomas E. Hutson	2011	10
12	Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies. Journal of Clinical Oncology ·M. Gore, J.T. Beck, Jacob Fierro, Timothy Eisen, Cezary Szczylik, S. Négrier, Thomas E. Hutson, Andreas Brueckner, J. Kalmus, Bernard Escudier	2010	1
13	Phase II study of BAY 73–4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer Journal of Clinical Oncology ·Timothy Eisen, Heikki Joensuu, Paul Nathan, P. Harper, Marek Z. Wojtukiewicz, Steve Nicholson, Esengül Liman Yazıcı, Piotr Tomczak, Amy J. Wagner, David I. Quinn	2009	10
14	Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 Nature Genetics ·Christopher I. Amos, Xifeng Wu, Peter Broderick, Ivan P. Gorlov, Jian Gu, Timothy Eisen, Qiong Dong, Qing Zhang, Xiangjun Gu, Jayaram Vijayakrishnan, Kathleen E. Sullivan, Athena Matakidou, Yufei Wang, Gordon B. Mills, Kimberly F. Doheny, Ya-Yu Tsai, Georges Okala, Sanjay Shete, Margaret R. Spitz, Richard S. Houlston Hit paper breakdown →	2008	879
15	857 RANDOMIZED PHASE III TRIAL OF SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): IMPACT OF CROSSOVER ON SURVIVAL European Urology Supplements ·Timothy Eisen, Ronald M. Bukowski, Michael Staehler, Cezary Szczylik, Stéphane Oudard, Walter M. Stadler, Ronit Simantov, Minghua Shan, Bernard Escudier	2007	3
16	RANDOMISED PHASE III TRIAL OF THE MULTIKINASE INHIBITOR SORAFENIB (BAY 43-9006) IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) European Urology Supplements ·Bernard Escudier, Cezary Szczylik, Timothy Eisen, Stéphane Oudard, Walter M. Stadler, Brian Schwartz, Minghua Shan, Ronald M. Bukowski	2006	14
17	382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study European Journal of Cancer Supplements ·Simon Pacey, Mark J. Ratain, Ellie K. Bohm, Henry Xiong, Amita Patnaik, Timothy Eisen, Donna Eaton, R.J. Bunnik, Brian Schwartz, I. Judson	2004	1

About Timothy Eisen

Timothy Eisen is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Nephrology, Reproductive Medicine and Pharmacology, having authored 17 papers that have together received 3.5k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (11 papers), Cancer Genomics and Diagnostics (7 papers), Multiple and Secondary Primary Cancers (2 papers), Genetic Associations and Epidemiology (2 papers), BRCA gene mutations in cancer (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Economic and Financial Impacts of Cancer (2 papers) and Renal and related cancers (2 papers). The work is most often cited by research in Cancer Research (1.0k citations), Hepatology (497 citations), Pulmonary and Respiratory Medicine (2.0k citations), Oncology (949 citations) and Molecular Biology (1.8k citations). Timothy Eisen has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Bernard Escudier, Ferrán Algaba, Alan Horwich, Jean Jacques Patard, Manuela Schmidinger, Camillo Porta, Vincent Khoo, Athena Matakidou, Richard S. Houlston and Peter Broderick. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Nature Genetics and European Journal of Human Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact